Non-coding RNA-based therapeutics in cancer therapy: An emphasis on Wnt/β-catenin control
European Journal of Pharmacology, ISSN: 0014-2999, Vol: 951, Page: 175781
2023
- 7Citations
- 6Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations7
- Citation Indexes7
- CrossRef4
- Captures6
- Readers6
- Mentions1
- News Mentions1
- 1
Most Recent News
Reports from Islamic Azad University Add New Data to Findings in Cancer (Non-coding Rna-based Therapeutics In Cancer Therapy: an Emphasis On Wnt/beta-catenin Control)
2023 JUL 18 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Daily -- Researchers detail new data in Cancer. According to news
Review Description
Non-coding RNA transcripts are RNA molecules that have mainly regulatory functions and they do not encode proteins. microRNAs (miRNAs), lncRNAs and circRNAs are major types of this family and these epigenetic factors participate in disease pathogenesis, especially cancer that their abnormal expression may lead to cancer progression. miRNAs and lncRNAs possess a linear structure, whereas circRNAs possess ring structures and high stability. Wnt/β-catenin is an important factor in cancer with oncogenic function and it can increase growth, invasion and therapy resistance in tumors. Wnt upregulation occurs upon transfer of β-catenin to nucleus. Interaction of ncRNAs with Wnt/β-catenin signaling can determine tumorigenesis. Wnt upregulation is observed in cancers and miRNAs are able to bind to 3′-UTR of Wnt to reduce its level. LncRNAs can directly/indirectly regulate Wnt and in indirect manner, lncRNAs sponge miRNAs. CircRNAs are new emerging regulators of Wnt and by its stimulation, they increase tumor progression. CircRNA/miRNA axis can affect Wnt and carcinogenesis. Overall, interaction of ncRNAs with Wnt can determine proliferation rate, migration ability and therapy response of cancers. Furthermore, ncRNA/Wnt/β-catenin axis can be utilized as biomarker in cancer and for prognostic applications in patients.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0014299923002923; http://dx.doi.org/10.1016/j.ejphar.2023.175781; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85159444846&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37179043; https://linkinghub.elsevier.com/retrieve/pii/S0014299923002923; https://dx.doi.org/10.1016/j.ejphar.2023.175781
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know